Inhibitors of JAKs/STATs and the kinases: a possible new cluster of drugs

被引：73

作者：

Luo, C

Laaja, P

机构：

[1] Oklahoma Med Res Fdn, Oklahoma City, OK 73104 USA

[2] Abo Akad Univ, Turku 20520, Finland

[3] Univ Turku, Turku Ctr Biotechnol, SF-20500 Turku, Finland

来源：

DRUG DISCOVERY TODAY | 2004年 / 9卷 / 06期

关键词：

D O I：

10.1016/S1359-6446(03)03014-9

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

JAK(s)/STAT(s) relay cytokine signals through tyrosine site-specific phosphorylation of the proteins involved in cellular responses for the activation and proliferation of bone marow-derived cells. In recent years, the constitutive or elevated expression of JAK/STAT has been found in cancer cells and oncogene transfected cells, and has been shown to be involved in the immune rejection of allografts and the inflammatory processes of autoimmune diseases. This review discusses the strategies for screening and rational design of selective, potent JAK/STAT and kinase inhibitors that are either ATP-competitive, naturally derived or synthetic, as well as other unique inhibitors and analogues for different therapeutic indicators.

引用

页码：268 / 275

页数：8

共 57 条

[1]

Alas S, 2003, CLIN CANCER RES, V9, P316

[2] Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles [J].